Sigma Healthcare Shares Sit Between Two Key Levels, In Battle For Direction

Sigma Healthcare shares (ASX:SIG) are a technical inflection point, after a 14% rebound off multi-month lows ran into resistance at the 200-day moving average. The stock is now consolidating between two closely watched support and resistance levels in a period that could well define the remainder of calendar 2026.

The SIG share price back 2.83% on Wednesday to close at A$2.75, trimming gains from what had been an impressive recovery from recent lows. The move places the stock squarely between its 50-day SMA at A$2.706 and its 200-day SMA at A$2.81, with both levels tested this week.  The pullback also came from an overbought position, with the RSI having sat at 72 before cooling to a more neutral 55.53.

The A$2.706 to A$2.81 range has emerged as the pivotal zone to watch for the day. A sustained close above the 200-day SMA would likely reopen upside momentum and bring the YTD break even level back into view, while a break below the 50-day SMA would suggest the bounce off lows has run its course.

The Latest Look

There has been plenty to digest on the fundamental side, with Sigma’s Annual General Meeting (AGM) and its first full-year results since merging with Chemist Warehouse Group (CWG) both providing markets with significant data points to digest.

At the AGM, management delivered a Q1 FY27 trading update that painted a broadly constructive picture of the combined network’s performance. Australian Chemist Warehouse branded stores reported a 12.1% increase in sales for the period from 1 July to 16 October 2026, with like-for-like growth of 9.8%. International Chemist Warehouse stores delivered an even stronger result, with sales surging 30.2% on a constant-currency basis, or 15.8% like-for-like, underscoring the brand’s growing offshore traction.

Network expansion is proceeding at pace. Sigma is on track to open 14 Chemist Warehouse stores and 42 Amcal and Discount Drug Stores in Australia during the first half of FY27, alongside 19 international store openings. All 11 AGM resolutions were passed, including executive long-term incentive plans and director re-elections, suggesting no meaningful shareholder friction at the governance level.

The FY26 full-year results, Sigma’s first as a merged entity, provided the fundamental baseline markets are now working with. Full-year revenue climbed 15.5% to A$10.8 billion, while Normalised EBIT rose 20.6% to A$1.09 billion and Normalised NPAT increased 22.3% to A$732.3 million. The balance sheet has been actively managed, with net debt reduced to A$663 million and the net debt-to-EBITDA leverage ratio brought down to a conservative 0.57 times — a figure that gives management meaningful financial flexibility as the integration continues.

On the synergy front, Sigma delivered A$32.6 million in integration synergies during FY26 and remains on track to reach its target of A$100 million per annum by FY29. With roughly A$67 million in planned synergies still to be realised over the coming years, execution on this pathway will remain a key valuation driver.

Management also flagged the growing contribution of GLP-1 weight-loss and diabetes medicines as a structural demand tailwind for the network, positioning the pharmacy channel as a key distribution point for one of the fastest-growing therapeutic categories globally. Offshore expansion continues, with a Memorandum of Understanding signed with GreenLight Healthcare targeting UK store openings, and a new 23,000 square metre distribution hub launched in Wiri, Auckland, to scale New Zealand operations.

There were some challenges highlighted during the AGM, as management acknowledged persistent softness in high-margin discretionary categories, including ladies’ fragrances, vitamins, and dietary supplements, as cost-of-living pressures continue to weigh on consumer spending in these segments. The shift in product mix toward prescription medicines, including GLP-1s, while a long-term growth driver, carries structurally lower margins than the retail beauty and wellness categories it is partially displacing in the near term.